Product Description
TAS266 is a novel agonistic tetravalent Nanobody® targeting the DR5 receptor. (Sourced from: https://oak.novartis.com/24267/)
Mechanisms of Action: D5 Agonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01529307 |
CTAS266X2101 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2012-09-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|